jnj-64565111
Peptideexperimental
Clinical trial activity
15 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jul 12, 2016 (NCT02862431)
Timeline
Indications
Mechanism of action
GLP1R agonist
- Glucagon receptorAGONIST
GCGR agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297576 ↗
Also known as
- jnj-64565111
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06482112 | Phase 2 | Jul 29, 2024 | Merck |
| NCT06465186 | Phase 2 | Jul 12, 2024 | Merck |
| NCT06701305 | Phase 1 | Jun 13, 2024 | Merck |
| NCT06052566 | Phase 1 | Nov 21, 2023 | Merck |
| NCT05877547 | Phase 2 | Jun 23, 2023 | Merck |
| NCT06836037 | Phase 1 | Sep 5, 2022 | Merck |
| NCT04944992 | Phase 2 | Aug 4, 2021 | Merck |
| NCT03618160 | Phase 1 | Aug 6, 2018 | Janssen Pharmaceutica NV |
| NCT03606057 | Phase 1 | Jul 13, 2018 | Janssen Pharmaceutica NV |
| NCT03586843 | Phase 1 | Jun 29, 2018 | Johnson and Johnson |
| NCT03586830 | Phase 2 | Jun 26, 2018 | Johnson and Johnson |
| NCT03546205 | Phase 1 | Jun 6, 2018 | Johnson and Johnson |
| NCT03486392 | Phase 2 | Mar 26, 2018 | Johnson and Johnson |
| NCT03235219 | Phase 1 | Aug 1, 2017 | Johnson and Johnson |
| NCT02862431 | Phase 1 | Jul 12, 2016 | Johnson and Johnson |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 7 | 7 | 2 | 2021 |
| Johnson and Johnson | For profit | 6 | 6 | 2 | 2016 |
| Janssen Pharmaceutica NV | For profit | 2 | 2 | 1 | 2018 |
3 organizations
Page 1 / 1